Nasdaq · Healthcare
Harmony Biosciences Holdings, Inc. (HRMY)
As-reported financials and recent SEC filings for Harmony Biosciences Holdings, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$868.5M
Net income
$158.7M
Net margin
18.3%
Diluted EPS
$2.71
ROE
18.2%
P/E (TTM)
14.3×
Market cap
$2.05B
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M |
| Gross profit | $670.1M | $557.9M | $460.8M | $354.4M | $249.9M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M |
| Diluted EPS | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →1442026-06-24
View on EDGAR →1442026-06-09
View on EDGAR →1442026-06-05
View on EDGAR →1442026-06-04
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →42026-05-18
View on EDGAR →Go deeper on HRMY
Search Harmony Biosciences Holdings, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.